Welcome to our dedicated page for RJAC news (Ticker: RJAC), a resource for investors and traders seeking the latest updates and insights on RJAC stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect RJAC's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of RJAC's position in the market.
Jackson Acquisition Company (NYSE: RJAC.U) announces that starting January 31, 2022, holders of its Units can opt to separately trade shares of Class A common stock and redeemable warrants. Each Unit includes one share of Class A common stock and half a warrant, with each whole warrant allowing purchase at $11.50 per share. The new trading symbols will be RJAC for Class A common stock and RJAC.WS for warrants on the NYSE. Those wishing to separate units must contact the transfer agent, Continental Stock Transfer & Trust Company.
Jackson Acquisition Company successfully closed its initial public offering, selling 20,000,000 units at
Jackson Acquisition Company has priced its initial public offering (IPO) of 20,000,000 units at
FAQ
What is the market cap of RJAC (RJAC)?
